Comparing Lantheus (NASDAQ:LNTH) and Haleon (NYSE:HLN)

Haleon (NYSE:HLN) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Institutional and Insider Ownership

6.7% of Haleon shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Haleon has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.

Valuation and Earnings

This table compares Haleon and Lantheus”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haleon	$14.35 billion	3.30	$1.84 billion	$0.39	26.97
Lantheus	$1.53 billion	3.63	$312.44 million	$3.52	22.88

Haleon has higher revenue and earnings than Lantheus. Lantheus is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Haleon and Lantheus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haleon	12.86%	17.65%	8.58%
Lantheus	16.55%	36.99%	20.55%

Analyst Recommendations

This is a summary of current ratings and price targets for Haleon and Lantheus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haleon	0	5	4	2	2.73
Lantheus	0	0	6	0	3.00

Haleon presently has a consensus target price of $12.33, suggesting a potential upside of 17.16%. Lantheus has a consensus target price of $130.50, suggesting a potential upside of 62.01%. Given Lantheus’ stronger consensus rating and higher probable upside, analysts clearly believe Lantheus is more favorable than Haleon.

Summary

Lantheus beats Haleon on 10 of the 15 factors compared between the two stocks.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

About Lantheus

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.